Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Sunnybrook Health Sciences Centre
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05465876CT.gov Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · COVID-19
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Evusheld (this asset) | Sunnybrook Health Sciences Centre | P2 | CCC · 53 |
| Recombinant Adenovirus Type 5 Carrying The Gene For Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) Spike Glycoprotein (Cansino Biologics) | Seventh Medical Center of PLA General Hospital | P3 | BBB |
| Serostim | ClinAmygate | P4 | BB |
| cc-220 | Nguyen Thi Trieu, MD | P4 | BB |
| Tocilizumab | National Cancer Institute (NCI) | P3 | BB |
| Oxygen | Jay C. Buckey Jr. | P4 | BB |
| Sotrovimab | Fred Hutchinson Cancer Center | P2/3 | B |
| Niclosamide | Cambridge University Hospitals NHS Foundation Trust | P2/3 | B |
| Gam-Covid-Vac | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | P3 | B |
+42 more in the COVID-19 cohort
Other indications for Evusheld
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Recombinant Adenovirus Type 5 Carrying The Gene For Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) Spike Glycoprotein (Cansino Biologics)Seventh Medical Center of PLA General HospitalBBB
- SerostimClinAmygateBB
- cc-220Nguyen Thi Trieu, MDBB
- TocilizumabNational Cancer Institute (NCI)BB
- OxygenJay C. Buckey Jr.BB
Citation
Floatz Terminal. Evusheld in COVID-19. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/evusheld-covid-19
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →